Event Chair – Industry Consultant, CBO Research Instruments Corporation
Keith Bisogno is Chair of the Global Cannabis Research Summit bringing his Fortune 500 experience to the conference leveraging his expertise in the legalization of cannabis spanning regulatory and policy matters, business supply chains, safety compliance and the emerging scientific landscape.
Bisogno recently spearheaded global business development initiatives for Thermo Fisher Scientific, including cannabis markets, where he led corporate efforts to engage regulatory, research and industry partners in the cannabis arena. He has also been a private cannabis industry investor since 2015 and lifelong advocate for cannabis science and social justice reform.
Keith Bisogno previously held a variety of senior-level corporate roles at Thermo Fisher Scientific, including Vice President Brand and Vice President Corporate Marketing where he executed global campaigns, commercial and digital marketing initiatives helping propel the world’s largest life science tools company beyond $22+ billion in sales with 70,000 employees in 50 countries.
Senior Editor, The Journal of Precision Medicine
Thomas L. Fare is currently the Senior Editor of the Journal of Precision Medicine. He also supports PlanetConnect as a Director of Strategic Alliances. Prior to his current roles, Dr Fare spent over 13 years with Merck & Co. and over 30 years in a variety of biotechnology and technology positions. He received his PhD in Electrical Engineering and Science at the University of Pennsylvania. He has authored or co-authored peer-reviewed papers in fields ranging from circuit design to gene profiling technologies. He uses his extensive experience in researching current topics to identify emerging technologies and cutting-edge research. Based on these searches, he identifies and engages potential authors and speakers on topics that address unmet needs in precision medicine.
Chief Scientific Officer and Co-Founder at Regional Pharma Consulting
Dr. Mudgett is a pharmaceutical scientific director and BioPharma consultant with over 30-years’ experience across biopharmaceuticals, technology platform and CRO companies, national laboratories, and academic institutions. Dr. Mudgett began his BioPharma career at Merck Research Laboratories where he headed a laboratory responsible for establishing new technology platforms and applying them to drug discovery and development. He became a founding member of the Genetically-Engineered Models department, tasked with taking an entrepreneurial approach to partnering with external research organizations to create an inception-to-impact return on investment with external providers in the US and EU arenas.
Dr. Mudgett then became External Lead – Pharmacology, a position with increasing responsibilities responsible for the execution of scientific, business development, managerial, financial, Lean Sigma, and IT delivery for translational BioPharma support of a diverse portfolio of programs in the global CRO arena (EU, US, CH) for Merck Research Laboratories. In 2016 Dr. Mudgett established JsM BioScience, LLC, successfully providing science and business development consultation services to Academic, Biotech/Technology Platform, CRO, and Scientific Conference Planning business. In late 2018 he merged his BioPharma consulting business to become Co-Founder and Chief Scientific Officer of Regional Pharma Consulting, LLC, with offices in Lebanon, NJ.
He currently is Adjunct Professor and Department Advisory Board chair, Department of Biology and Biotechnology, and member College of Science and Health Advisory Board at William Paterson University.
Dr. Mudgett serves as a Scientific Advisor to the Panel of Scientific Consultants for the International Mouse Phenotyping Consortium (IMPC), funded by the NIH Common Fund, as well as Scientific Advisory Board member for PHENOMIN, the French National Infrastructure for Mouse Phenogenomics.
In addition, John is a member of the BioPharma Research Council committee for helping to organize speakers and conference sessions for upcoming events focused on new technologies and their application to drug discovery and development.
Lastly, John has an established business providing custom wood-crafted products from historic woods to customers throughout the US and Europe (JsM Woodcraft) (www.JMWoodcraft.com). John is on LinkedIn, at [www.linkedin.com/in/jsmBioScience)
CEO and CSO of Supra Research and Development
Rob is an innovation solution provider with a strong experience base in Analytical Chemistry, Laboratory and Research team management, Scientific Education and company leadership.He is currently the Senior Executive for Scientific Affairs at ISURA, a non-profit organization dedicated to improving the safety and effectiveness of Natural Health Products through improved analytical technology and research. He has also founded a series of companies, including Supra Research and Development and Supra THC Services Inc. These companies are also focused on developing enhanced Analytical Chemical solutions; though analytical services, consulting services and contract research and development. He has been fortunate to be associated with a comprehensive and diverse team of highly qualified experts who are dedicated to produce positive social and economic benefits. This team enables me to have an impact much greater than my individual capabilities would allow.
In addition to his employment activities, he also owns and operates a hobby farm and he is a passionate supporter of Rugby development at the university level.
Professor, William Paterson University
Dr. Emmanuel S. Onaivi (B. Pharm, MSc, PhD) is Professor in the department of Biology at William Paterson University (WPU) in New Jersey, a Fulbright scholar and a Guest Scientist at the National Institute on Drug Abuse a part of NIH in Baltimore, MD. His research interests include the molecular biology of drug abuse and teaches Neural Basis of Behavior, Pharmacology, Bioseminar, and Anatomy and Physiology.
Professor Onaivi teaches cannabis as medicine in the Pharmacology course. He has authored and co-authored many papers and edited three books on cannabis including the Biology of Marijuana, Endocannabinoids: The brain and body’s marijuana and beyond, and Marijuana and cannabinoid research methods and protocols.
Professor Onaivi’s pioneering research on cannabis, its constituent cannabinoids and the natural cannabis compounds produced by the human body called endocannabinoids led to:
– Cloning of CB1 cannabinoid receptors in mice
– The discovery and identification of functional neuronal CB2 cannabinoid receptors
– Postsynaptic localization of CB2 cannabinoid receptors (CB2Rs)
– Ethnic and gender differences in cannabinoid receptors
– Creation and generation of cell type specific CB2R conditional knockout mice for which Dr. Onaivi and his collaborator Dr. Liu and the University have filed for global patent.
– Demonstration of the interaction between cannabinoid receptors and vanilloid receptors as a basis of why some like it hot and spicy and others do not. This research was competitively selected, and presented on Capitol Hill in Washington DC to show case Undergraduate student research before the US Congress.
Professor Onaivi was the recipient of William Paterson University Award for Excellence in Scholarship and creative expression in 2007 and 2015. The National Institute of Health funded his research titled Behavioral effects of CB2 receptors. He has supervised Doctoral, Pre- and Postdoctoral fellows, Masters and Undergraduate student research. He is a member of the society for Neuroscience, and Newsletter editor for the International Drug abuse Research Society, and most recently selected as the Editor in Chief for Journal of Drug and Alcohol Research.